EGFR and non-small cell lung carcinoma: Third-generation EGFR tyrosine kinase inhibitors (TKIs) osimertinib has been approved as the standard treatment for EGFR-mutated NSCLC patients, with median progression-free survival (PFS) and overall survival (OS) reaching 18.9 months and 38.6 months, respectively (5).